Study Objectives: Evaluate the hypnotic efficacy of gaboxadol, a selective extrasynaptic GABAA agonist (SEGA), in a phase advance model of transient insomnia. Design: A randomized, double-blind, cross-over study in which habitual sleep time was advanced by 4 h. Setting: Sleep research laboratories Participants: 109 healthy subjects (18-58 y) Interventions: Gaboxadol 5 mg, 10 mg, and 15 mg (GBX5, GBX10, GBX15) versus placebo (PBO). Zolpidem 10 mg (ZOL10) was used as an active reference. Measurements: Polysomnographic (PSG) and self-reported (s) sleep measures Results: Wakefulness after sleep onset (WASO) decreased (P <0.05) and total sleep time (TST) increased (P <0.001) in all treatments versus PBO. Latency to persistent sleep was shorter (P <0.05) than PBO for all treatments except GBX5. GBX10 and GBX15 increased slow wave activity (SWA; 0.75-4.5 Hz, P <0.001) and theta activity (4.75-7.75Hz; P <0.001) and reduced sigma activity (12.25-15.0 Hz; significant for GBX15 only, P <0.001) compared to PBO in NREM sleep EEG, in a dose-response manner. Zolpidem suppressed power density over a broad low frequency range including delta and theta frequencies (2.25-8.0 Hz, P <0.05) and also enhanced sigma activity (P <0.001). Self-reported sWASO and sTST improved for all treatments versus PBO (P <0.05). Self-reported sleep latency was reduced following GBX10 (P <0.05) and ZOL10 (P <0.001). Neither drug treatment was associated with residual effects the morning after treatment. Conclusions: Gaboxadol and zolpidem improved objective and subjective efficacy measures in this model of transient insomnia. The gaboxadol-induced enhancement of SWA and theta activity and the reduction of sigma activity contrasts with zolpidem's effects on the spectral EEG. These differences may reflect the different mechanisms of action of the two drugs. 
INTRODUCTION

GABOXADOL'S UNIQUE MODE OF ACTION HAS RE-CENTLY BEEN DESCRIBED AS DIRECT ACTIVATION OF EXTRASYNAPTICALLY LOCATED Γ-AMINOBUTYRIC
acid type A (GABA A ) receptors, specifically those with a configuration of α 4 β 3 δ subunits. 1 Receptors with the α 4 subunit are predominantly expressed in the cortex, limbic system, and thalamus. 2 The identified receptor selectivity and direct GABAergic effects have led to gaboxadol's characterization as a selective extrasynaptic GABA agonist (SEGA). 3 No other selective ligands of the α 4 β 3 δ receptor subtype have been reported to date.
Two SEGA properties distinguish gaboxadol from allosteric modulators of GABA such as traditional benzodiazepine and nonbenzodiazepine hypnotics (collectively termed benzodiazepine receptor agonists; BzRAs). First, gaboxadol is a direct GABA A agonist, whereas BzRAs are allosteric modulators of the actions of endogenous GABA. Second, the extrasynaptic location of the α 4 β 3 δ receptors has been associated with tonic GABA A activity, versus the phasic activity of synaptic GABA A receptors which mediate the effects of BzRAs. In addition, α 4 β 3 δ-containing GABA A receptors are insensitive to allosteric modulation by BzRAs. 4 The functional consequences of these pharmacological differences are yet to be fully characterized. However, human and animal studies have shown a consistent pattern of effects on sleep that differentiate gaboxadol from BzRAs and other GABAergic drugs.
Gaboxadol's effect on sleep has been characterized in both rats and humans. In rats, gaboxadol has been shown to increase time in both REM and NREM sleep, whether administered at the beginning of either the light or dark period. 5 Augmentation of lowfrequency components of the sleep electroencephalogram (EEG) has also been reported. 5 In healthy young adults, gaboxadol (20 mg) has been shown to increase visually scored slow wave sleep (SWS) by more than 20 minutes and enhance spectral power in NREM EEG frequencies <8 Hz. 6 In healthy elderly subjects, gaboxadol (15 mg) has been shown to reduce the number of PSG awakenings and total wake time during a single night of treatment. 7 Low-frequency EEG power in NREM was also enhanced, self-reported total sleep time was increased, and sleep latency was shortened. Mathias and colleagues have found comparable effects of gaboxadol (15 mg) given on 3 consecutive nights to healthy elderly subjects. 8 Following a late afternoon nap, which can reduce homeostatic sleep drive during the subsequent night, gaboxadol 20 mg, taken prior to nocturnal sleep, has been shown to reduce sleep latency, increase both total sleep time and SWS, and enhance delta and theta activities in NREM sleep. 9 A recent report indicates that gaboxadol (15 mg) improved traditional hypnotic efficacy measures during shortterm administration in patients with primary insomnia. 10 The present study was designed to evaluate the effect of gaboxadol (5 mg, 10 mg, and 15 mg), as compared to placebo, upon phase-advanced sleep. A phase advance typically involves moving bedtime earlier by 2-5 h and produces predictable sleep disruption. The first few hours of the sleep period occur during the "forbidden zone" for sleep, when the circadian arousal system promotes alertness thereby reducing the likelihood of sleep. 11 A key advantage of the acute phase advance model is that it reflects transient insomnia well. Transient insomnia often results from time shifts and typically does not allow an individual to obtain adequate sleep in the normally allowed period of time.
Drug treatment effects have been demonstrated in prior studies using a phase-advance procedure. 12, 13 Zolpidem 10 mg has proven hypnotic efficacy and was used in this study as an active reference.
The primary study objective was to evaluate the effect of gaboxadol on traditional polysomnographic (PSG) and self-reported efficacy measures in this transient insomnia model. The secondary objectives were to evaluate visual and spectral measures of slow wave sleep, residual sedative effects, and safety and tolerability.
PATIENTS AND METHODS
Patients and Screening Procedures
One hundred nine (109) healthy subjects (men and women), between the ages of 18 and 58 years were recruited for this randomized, double-blind, placebo-controlled, 5-way cross-over study. Subjects were excluded if they had any chronic sleep disturbance that caused clinically significant distress or impairment in social, occupational, or other important areas of functioning based upon DSM-IV criteria and a Pittsburgh Sleep Questionnaire Inventory (PSQI) 14 score of >5. Subjects were required to report normal sleep patterns during the past 3 months or more, defined as a standard bedtime between 21:00 and 24:00 on at least 5 of 7 nights per week, with a reported sleep duration between 6.5 and 8.5 h. Shift workers or subjects who maintained/ initiated an irregular sleep/wake schedule during the preceding 1 month or during the study were excluded. Women of childbearing potential who used a medically acceptable method of contraception were allowed to participate. Subjects were excluded if they had: a history of severe allergy or hypersensitivity, a known sensitivity to benzodiazepines, zolpidem, or any substance in the study medication; evidence of any clinically significant medical abnormality or chronic disease; a history of psychiatric disorder or clinically significant abnormality of the cardiovascular, respiratory, hepatic, or renal systems. Subjects had not taken over-the-counter medications within 7 days of the study (except accepted birth control medication, and nonsteroidal anti-inflammatory drugs/acetaminophen for infrequent headaches/pain not considered clinically significant) and other medications within 4 weeks (or fluoxetine within 3 months). Subjects were also excluded if they had: a history of alcohol or drug abuse (according to DSM-IV); consumed >3 alcoholcontaining beverages daily (glasses of wine/beer or its equivalent) or >300 mg caffeine daily; smoked >5 cigarettes a day and could not forego smoking for up to 14 h while in the laboratory; participated in a clinical trial within 30 days prior to screening; or were in a previous gaboxadol study.
Procedures
This study was conducted at 6 sleep laboratories in the United States under a common protocol which was approved by an Institutional Review Board for each site. Prior to initiating study procedures, subjects gave written informed consent. The study consisted of a screening session, 5 treatment sessions, and a follow-up visit. The treatments consisted of gaboxadol (5 mg, 10 mg, and 15 mg), zolpidem (10 mg), and placebo. The screening session consisted of a medical screening visit followed 7-14 days later by a PSG screening night and multiple sleep latency test (MSLT) the following day. There were 5-14 days between PSG screening night and first treatment session, 5-9 days between the start of each of the treatment sessions, and 3-7 days between the last treatment session and the follow-up visit. On the screening PSG night, respiratory effort and airflow, oxygen saturation and leg electromyogram were recorded, in addition to the routine PSG measures, to exclude subjects with sleep-related breathing disorders and periodic limb movement disorder. Subjects were excluded if they had a mean periodic leg movement arousal index >10 per hour or a mean apnea/hypopnea index >10 per hour.
Screening PSG recording in the sleep laboratory began 8 h before the subject's habitual rise time and the total recording time was 8 h on all PSG nights. Habitual rise time was determined between the first screening visit and PSG screening night (7-14 days). The MSLT was conducted during the day after the PSG termination on Night 1 to exclude subjects with moderate/severe levels of daytime sleepiness as defined by a mean MSLT score <10 minutes.
On Day 1 of the first treatment session, the subjects were randomly allocated to one of 10 treatment sequences in a William's Latin Square cross-over design. Each treatment session consisted of 2 consecutive nights at the sleep laboratory for PSG evaluation. On the first night, subjects received placebo in a single-blind fashion 30 minutes before bedtime. On the second night, subjects received either placebo, zolpidem, or one of the 3 gaboxadol doses in a double-blind fashion. Bedtime and rise time on Night 2 was 4 h earlier than on Night 1.
Subjects were requested to maintain a regular sleep/wake cycle between the treatment sessions. A regular sleep/wake schedule was required from the PSG/MSLT screening visit until the end of the last treatment night (except on the day when the phase advance was required). A regular sleep/wake cycle was defined as maintaining the subject's habitual bedtime and sleep duration within 120 minutes of the mean habitual sleep times for each subject. In addition, all subjects were instructed to sleep 8 h each night for the 2 nights prior to each treatment night PSG. If any subject retired to bed (to initiate sleep) or had a sleep duration >60 minutes different from habitual sleep times on the 2 nights prior to the first night of each treatment session, the subject was rescheduled at a later date. Regularity of the sleep/wake schedule was assessed by sleep diary and actigraphy. During the study, no strenuous exercise was allowed <6 h before entering the sleep laboratory and no caffeine-containing drinks allowed after 15:00 on any PSG night. During the treatment periods, the subjects were not allowed to go to bed or to take a nap during the daytime.
All PSGs/EEGs were analyzed by central laboratories without access to treatment codes. Visual scoring was performed by Clinilabs (New York, US), screening MSLT was scored under the supervision of an author (JKW), and EEG spectral analysis was performed by the Surrey Sleep Research Centre (Guildford UK), under the supervision of an author (DJD).
Dependent Measures
Traditional hypnotic efficacy variables were extracted from standardized visual PSG scoring 15 and included latency to persistent sleep (LPS; time in minutes from PSG onset to the beginning of 10 consecutive minutes of sleep), wake after sleep onset (WASO: the number of minutes scored as wake from LPS to the end of the PSG), total sleep time (TST; time spent in NREM and REM sleep excluding movement time) and number of awakenings (NAW; number of times from sleep onset [first epoch of non-wake] that at least one epoch was scored as wake and was immediately preceded by one or more epochs scored as sleep). Self-reported efficacy measures of sleep were collected on a morning questionnaire and included time to sleep onset (sTSO), total sleep time (sTST), number of awakenings (sNAW) and total duration of night awakenings (sWASO).
SWS was measured and analyzed with 2 separate methods. Firstly, the amount of stage 3 and 4 NREM sleep combined was determined from visually scored sleep stage data. Secondly, power spectral analysis of the NREM EEG provided slow wave activity (SWA; 0.75-4.5 Hz) values. Power spectra analysis was performed as follows. All PSG signals were converted to European Data Format (EDF) and transferred in a blinded fashion to the central laboratory. The EDF files as well as the corresponding and synchronized time series of sleep stages were imported into VitaSCORE software 1.22 (Temec Instruments BV, Kerkrade, The Netherlands). All sleep recordings were visually inspected and segments that could lead to spurious power spectra (fastor slow-frequency artifact such as that which occurs with body movement or excessive sweating) were annotated with a temporal resolution of 1 sec. Epochs that were annotated as artifacts in the EEG were not included. The number of recordings excluded from spectral analysis because of >2 hours of poor data quality in each condition were: placebo, 3; 5 mg, 3; 10 mg, 3; 15 mg, 5; and zolpidem, 2. Power spectra were computed per 4-sec epoch by applying a Fast Fourier Transform routine implemented in VitaScore. A squared cosine function was used as the tapering window and a 1-sec overlap between consecutive 4-sec epochs was applied. Power spectra between 0 and 31. Here we only report power spectra during all NREM sleep epochs (i.e., stages 1, 2, 3, 4 combined).
Next day residual effects were assessed by Bond and Lader visual analogue scales, digit symbol substitution test (DSST; 90-s duration), visual reaction time (VRT; 10-min duration), and Rey Auditory Verbal Learning Test (RAVLT; measures anterograde amnesia). These tests were conducted 30 minutes and 3 h after lights on in a structured order. The RAVLT was also conducted prior to dosing on Night 2 to measure retrograde amnesia.
Tolerability and safety was assessed by monitoring adverse events, hematology, biochemistry, ECG, neurological examination, and vital signs assessments.
Statistical Analysis
PSG, self-reported sleep (except sNAW), and residual effect measures were analyzed using a predefined analysis plan with an analysis of variance (ANOVA) model including terms for treatment, study site, period, and sequence as fixed effects and a term for subjects within sequence as a random effect, with natural log transformation when justified. Evaluation of sNAW was carried out using a Wilcoxon signed-rank test. When ANOVA revealed a significant main effect of treatment, contrasts were used to compare mean endpoint measures between gaboxadol doses and placebo, and for exploratory purposes to confirm the validity of the model, between zolpidem and placebo. Sample size determination was made for comparison of an active drug condition versus placebo on PSG TST. No correction for multiple comparisons was used since the study was designed primarily to find one or more doses of gaboxadol which differed from placebo on a small number of PSG measures (LPS, WASO, TST, NAW, and minutes of SWS), and self-report measures (sTST, sTSO, sNAW, sWASO). The statistical comparisons for the remainder of the PSG and selfreported sleep variables were exploratory.
Only subjects who received all double-blind treatments, did not have a major protocol deviation, met inclusion/exclusion criteria and had complete treatment night PSGs were included in the efficacy analyses -per protocol set (PPS). Subjects who had at least one post-baseline assessment and took at least 1 dose of double-blind medication were included in the full analysis set (FAS). Tests for residual sedation were analyzed using the FAS using a similar model to the efficacy analysis. Assessment of safety and tolerability included all randomized subjects who took at least 1 dose of double-blind treatment (all subjects treated set; ASTS) and are summarized using descriptive statistics. Assignment of subjects to the PPS, FAS, and ASTS was performed prior to unblinding.
Spectral power data were log-transformed prior to statistical testing. Effects of treatment were evaluated by a repeated measures analysis of variance using SAS PROC MIXED, with fixed effect factors for subject, treatment, period (1 to 5), and frequency band (the 15 adjacent bands, each of width 1 Hz, from 0.25 to 15.0 Hz) as a repeated measure with the Compound Symmetric variance-covariance matrix option, and including the condition by frequency band interaction. Separate analyses of variance were carried out for each frequency band with fixed effect factors for subject, condition, and period. Because the number of frequency bands (23 in total) of interest was not limited a priori, Bonferroni correction for multiplicity was applied to the spectral data analysis. For the tabular and graphical presentation, all data were expressed relative to the placebo condition and geometric means were computed.
RESULTS
A total of 380 subjects were screened to randomize 109. Of these 109 subjects, 2 did not receive randomized medication and 1 had no post-baseline efficacy assessment. The PPS also excluded an additional 24 subjects for the following (primary) reasons: withdrawal of consent (9), missing PSG data (5), MSLT <10mins (1), positive urine drug screen during treatment (8) , and noncompliance with regular sleep schedule (1). There were therefore 82 subjects in the PPS, 106 subjects in the FAS, and 107 subjects in the ASTS.
For the PPS, the mean baseline MSLT was 15.1 minutes (SD: 3.1) with a range of 10-20 minutes, and mean baseline PSQI score was 1.67 (SD: 1.34) with a range of 0-5. The FAS showed similar baseline values. The PPS mean age was 31.5 years (SD: 10.2, range 18-58 years, inclusive) and the sex distribution was 45% males, 55% females. The FAS and ASTS had age and sex distributions similar to the PPS. For the efficacy analyses of treatment, the FAS showed similar results to the PPS.
PSG, self-report, and spectral analyses data reported below are from the double-blind night of each treatment session, i.e., Night 2. Data from Night 1 (single-blind placebo) preceding Night 2 of the placebo condition are also presented below for the purpose of demonstrating the effect of the phase advance procedure upon sleep. Table 2 contains the means for PSG variables for placebo, zolpidem, and gaboxadol conditions. Examination of data from Nights 1 and 2 of the placebo condition clearly demonstrated the sleep disruptive effects of the phase advance procedure in healthy alert individuals (Table 1 ). There were significant detrimental effects on both PSG and self-reported efficacy measures of sleep initiation and maintenance. The effect on the number of night awakenings, although significant, was minimal. There were also minimal effects on SWS and stage 1. The major disruption to sleep stage architecture focused on stage 2 and REM. Latency to REM was also significantly delayed.
Polysomnography Variables
The zolpidem and placebo conditions were compared to assess the sensitivity of the phase-advance model to the effect of a standard hypnotic. Mean LPS with zolpidem was 22 minutes less than placebo (P <0.001) and mean WASO was reduced by about 30 minutes (P <0.001). As a result, zolpidem increased mean TST by about 50 minutes compared with placebo (P <0.001). The mean NAW was also lower than placebo in the zolpidem condition (P <0.05). Thus, assay sensitivity was demonstrated on these traditional hypnotic efficacy variables. With zolpidem, the amount of SWS increased (P <0.001) and stage 2 decreased (P <0.001) relative to placebo. Stage 1 and REM did not differ between zolpidem and placebo.
TST with each dose of gaboxadol was approximately 30 min- (Table 2 ) revealed a doserelated increase in SWS with gaboxadol (P <0.05 to 0.001).The absolute difference in SWS with gaboxadol ranged from approximately 5 to 22 minutes. The amounts of stage 1 and REM in all drug conditions did not differ from placebo. REM latency differed (reduction) from placebo only with the gaboxadol 10-mg condition (P <0.001).
EEG Spectral Analyses
Compared to placebo, gaboxadol enhanced, in dose-related fashion, EEG power density during NREM sleep in the low frequency range, including the delta and theta frequencies (0.25-8.0 Hz; see Fig 1, Tables 3 and 4) . Gaboxadol 10 mg and 15 mg enhanced EEG power density up to 8-9 Hz (P <0.001). Furthermore, an enhancement of the 8.25-9.0 Hz bin was also observed for the 10-mg dose (P <0.05). For the 5-mg dose, enhancement was observed only for 5.25-6.0 Hz (P <0.05). When power density was calculated for the SWA band (0.75-4.5 Hz), enhancements relative to placebo were observed for the gaboxadol 10-mg and 15-mg (P <0.001) conditions. No significant effects on SWA were observed for gaboxadol 5 mg. Gaboxadol 10 mg and 15 mg suppressed power density in the high alpha band (10.25-12.0 Hz)(P <0.05 and P <0.001, respectively). In the spindle frequency range (sigma; 12.25-15.0 Hz), the 15-mg dose suppressed power density.
Zolpidem suppressed power density over a broad low frequency range including the delta and theta frequencies (2.25-8.0 Hz; P <0.05 to 0.001). In lowest frequency bin (0.25-1.0 Hz), zolpidem enhanced power density relative to placebo (P <0.05). This explains why overall within the SWA frequency band (0.75-4.5 Hz), which encompasses part of the lowest frequency bin as well, the reduction in SWA with zolpidem did not achieve statistical significance. Zolpidem also enhanced NREM sleep power density in the spindle frequencies (P <0.001). For the higher frequency bands, no significant differences from placebo were observed in any condition. 
Self-reported Sleep Variables
Self-reported estimates of sleep collected on the morning questionnaire are shown in Table 5 . A longer sTST was found for all drug conditions as compared with placebo (P <0.05 for each). sTST increased by 23, 28, and 34 minutes following administration of 5-mg, 10-mg, and 15-mg doses of gaboxadol, as compared with placebo. All doses of gaboxadol, as well as zolpidem reduced sNAW (P <0.001, for each) and sWASO (P <0.05, for each), as compared to placebo. sTSO was shortened compared to placebo only for the gaboxadol 10-mg dose (P <0.05) and for zolpidem (P <0.001); however, when an extreme outlier in the 15 mg condition was removed (this subject reported a time to sleep onset of 420 minutes and reported a total sleep time of 1050 minutes), sTSO was also shorter with gaboxadol 15 mg than with placebo (P = 0.026).
Safety Measures
Both gaboxadol and zolpidem were well tolerated and had favorable safety profiles. There were no serious adverse events and no adverse events that led to withdrawal from the study. Adverse events (AEs) with the highest incidences (any condition) were nausea, headache, dizziness, hypertension, dysmenorrhea, infection, and vomiting ( Table 6 ). The majority of AEs were mild or moderate in severity and occurred in only 1 or 2 subjects in each group.
Hematology, biochemistry, physical, and neurological tests were conducted at screening and following conclusion of the study for safety purposes and, therefore, cannot be analyzed by study condition. There were no clinically relevant changes in hematology, biochemistry, physical examination, or ECG recordings in any subject. Analysis of safety-related data included all subjects receiving at least one dose of study drug. On the Bond and Lader visual analog scales completed 30 minutes after PSG termination, alertness was rated as being higher than placebo in all gaboxadol conditions (P <0.05 to <0.01). Three hours after PSG termination there were no group differences. There were no consistent effects of gaboxadol, relative to placebo, on calmness and contendedness. Zolpidem did not differ from placebo on any of these scales.
DSST number correct and visual reaction time did not differ significantly between placebo and any other condition at either 30 minutes or 3 h post-PSG. RAVLT results showed no impairment of memory for word lists and recall trials presented prior to drug ingestion at night (retrograde). For RAVLT tests which involved morning presentation and recall of the word list (i.e., about 9 hours after drug ingestion) there was a decrease in immediate recall on trial 4 (but not trials 1, 2, 3, or 5), as compared to placebo, in the gaboxadol 5 mg and 15 mg and the zolpidem conditions (P <0.05). No differences from placebo were found in either the 30-minute or 3-h delayed recall testing periods with any gaboxadol dose, but recall was worse at both time points in the zolpidem condition (P <0.005). 
DISCUSSION
Evaluation of the sleep disruption produced by the phase advance procedure aids in the understanding of the observed treatment effects. In the present study, the expected changes in traditional hypnotic efficacy measures were produced by the 4-hour phase advance. On average, LPS was delayed about 20 minutes, WASO increased about 35 minutes and TST declined approximately 1 h with the phase advance as compared with sleep at habitual times. Self-reported sleep measures followed a similar pattern. Thus, as implemented in this protocol this manipulation provides a robust experimental method for evaluation of sleeppromoting interventions.
Exclusion of subjects with moderate or severe sleepiness appears critical to the success of this model of transient insomnia as does ensuring compliance to a regular sleep/wake cycle immediately prior to the phase advance. A prior study using a 3-h phase advance without exclusion of subjects who exhibited daytime sleepiness found that the sleep of approximately 50% of subjects was not disrupted despite the phase advance. 13 Indeed, an experimental study documented a significantly lower degree of sleep disruption in response to a 4-h phase advance in sleep time when basal sleepiness was moderately high, compared to alert individuals. 16 Improvement in sleep on all traditional efficacy measures (i.e., TST, WASO, LPS, NAW) with zolpidem 10 mg demonstrated assay sensitivity for hypnotic drug effects in this transient insomnia model. All PSG and self-reported variables assessing sleep induction and sleep maintenance were significantly better with zolpidem than with placebo. Increases in TST were accounted for by increased amounts of stage 2 and SWS. Stage 1 and REM were not different from placebo.
In this study, significant sleep inducing effects of gaboxadol 10 mg and 15 mg were observed, whether assessed with PSG or selfreport, and there was a suggestion of a dose-response for LPS. For WASO the gaboxadol dose-response curve was flat with significantly reduced, and largely comparable values, at all 3 doses. The magnitude of effects of 15 mg gaboxadol on LPS and TST in this study were slightly greater than those observed in a sample of patients with primary insomnia. 10 However, these differences may be related to the increased severity of sleep disturbance in this model of transient insomnia versus the insomnia patients.
Stage 1 sleep and slow wave sleep were minimally affected by the phase advance procedure, while stage 2 and REM sleep were reduced. Gaboxadol increased stage 2 but the predominant effect on sleep architecture was a dose-related increase in SWS. There was no effect on the amount of REM or stage 1 sleep with any dose.
No drug produced worse DSST or visual reaction time performance 9 hours after dosing. Recall of a word list presented about 9 hours after dosing was impaired on 3 of 7 recall opportunities with zolpidem (1 of 5 immediate recall trials and the 30-minute and 3-h delayed recall trials) and 1 of 7 recall opportunities with gaboxadol 5 mg and 15 mg (both immediate recall trial 4). Taken together these findings suggest that all active drug conditions were free of global residual effects, but mild memory impairment cannot be excluded for the drug conditions. Because of the phase advance procedure, morning residual effects testing typically occurred between approximately 02:30 and 05:00; thus, the detected impairment may reflect additive effects of the study drugs and a Gaboxadol in Transient Insomnia-Walsh et al The gaboxadol induced enhancement of power density in the delta and theta frequency range is in good agreement with previous studies. 6, 7 A suppression of spindle activity as observed in the present study was also previously reported. 6 To our knowledge, the power spectral analysis data from this study are the first demonstration of a dose-related increase in SWA with gaboxadol in humans. The dose-response observation supports the interpretation that the increase in SWA (SWS) is a characteristic of gaboxadol at doses within a tolerated and potentially therapeutic range and not simply observed at extreme doses.
The increased visually scored SWS with zolpidem has been reported in some previous studies of healthy individuals, although most studies show no change. 17 Spectral analysis provides a more detailed picture of effects on EEG waveforms. An earlier study in which visually scored SWS did not differ between zolpidem 10 mg and placebo, 18 power spectral analysis of sleep EEG in healthy young males found reductions in power between 1.25-2.5 Hz and between 5.25-10 Hz with zolpidem but no change in 0.25-1.0 Hz activity. Monti et al 19 reported increased power in the 0.25-1.0 Hz range (in the beginning of the sleep episode), but not at other frequencies. In the present study, zolpidem 10 mg increased EEG power density in the very lowest frequency band, 0.25-0.5 Hz, but did not alter the SWA frequency band; whereas gaboxadol produced a significant power density enhancement in SWA. Examination of individual 1 Hz frequency bins showed a significant increase in power in the lowest 1 Hz bin (0.25-1.0 Hz) for zolpidem, but a significant reduction in all other 1 Hz bins up to 11 Hz. Thus the increase in visually scored SWS with zolpidem 10 mg seems to be due to enhancement of EEG waveforms less than 1 Hz without an effect on the overall SWA frequency band.
Standardized visual scoring of sleep stages is based upon categorization of EEG patterns into a fixed number of stages. Quantitative analysis methods, such as power spectral analysis, has more flexibility and sensitivity with regard to analysing the EEG. Because the temporal unit of analysis is much shorter than a 30-second epoch and the frequency measurement unit can be varied a more fine-grained analysis is possible. This study clearly demonstrates that sleep-promoting drugs can elicit very different effects on spectral power during NREM sleep, even when traditional sleep stage scoring appears similar. Interestingly, the effect of gaboxadol upon power density across the spectral range studied here is reasonably similar to the effect of sleep deprivation and sleep restriction. 20 That is, during recovery sleep after sleep deprivation or sleep restriction spectral power consistently increases in both the delta and theta bands, and decreases in the sigma band, just as was observed with gaboxadol. The spectral profile induced by zolpidem or other BzRAs is very different-namely, reduced delta and theta, and increased sigma activity. 21 The clinical significance of these hypnotic-associated EEG patterns remains to be elucidated. However, the differing spectral analysis profiles in NREM of these 2 drugs may be related to the different mechanisms of actions of gaboxadol and zolpidem.
It is interesting to speculate that a sleep-promoting agent that elicits spectral changes similar to those observed during sleep following the development of an increased sleep debt, may be promoting sleep through mechanisms involved in homeostatic sleep regulation. Consistent with that hypothesis is the dose response characteristic of the increase in SWA with gaboxadol, similar to the increasing enhancement of SWA with increasing severity of sleep deprivation. Another observation which relates the neural activity of gaboxadol to those of natural sleep is the activation of c-Fos expression by ventrolateral preoptic area (VLPO) neurons by gaboxadol, at a level similar to the activation seen with spontaneous sleep. 22 Other GABAergic drugs produce much lower levels of c-Fos expression in VLPO neurons when administered at sleep-promoting doses. 23 Gaboxadol is a selective extrasynaptic GABA A agonist, preferentially activating α 4 -containing receptors, 1 whereas zolpidem preferentially binds to α 1 -containing receptors, 3 and these receptor subtypes have differing distributions throughout brain. 4 Saper and colleagues 22 have postulated that the sleep promoting effects of drugs which modulate GABA A via α 1 , α 2 , α 3 , or α 5 containing receptor subtypes may result from suppression of arousal centers normally inhibited by GABAergic neurons in the VLPO; whereas gaboxadol may promote sleep via reduction of inhibitory input to the VLPO from corticolimbic sites in which α 4 containing receptors are concentrated, including medial temporal and prefrontal cortex. Interestingly, these cortical areas, as well as others, have been shown to be more active in insomniacs than in controls during sleep. 24 The clinical significance of SWS/SWA has yet to be determined but there a number of lines of research which support the concept that enhanced SWS/SWA are indices of heightened sleep intensity, including: 1) enhanced SWA following sleep deprivation in proportion to the duration of prior wakefulness, 25 2) reduced amounts of SWA during nocturnal sleep following afternoon/evening naps, 26 3) a gradual decline in SWA across a night of sleep, 27 and 4) increased SWS following nights of fragmented sleep. 28 Additionally, experimental application to the cortex of sleep-regulating substances, which are endogenously produced during periods of activity, can induce increases in SWA in the EEG. 29, 30 There is also some evidence to suggest that SWS/SWA may Gaboxadol in Transient Insomnia-Walsh et al play a role in aspects of daytime function and specifically in somatic and cognitive restoration, including the consolidation of certain forms of procedural and declarative memory. In one study, for example, performance gains in a motor memory task were significantly correlated with peak SWA activity in the right parietal cortex, a region known to be associated with processing of visual-spatial information. 31 Low-frequency components in the EEG during NREM sleep have been hypothesized to be critical for reversing cortical synaptic potentiation which occurs during wakefulness. 32 , Reversal of cortical synaptic potentiation may be a process through which sleep facilitates memory, learning, sustained attention, and other cortical functions. 33, 34 Recently, druginduced SWS enhancement was associated with elimination of a deficit in sustained attention which typically occurs with sleep restriction. 35 Careful review of prior studies which have failed to demonstrate an effect of SWS deprivation on daytime function reveals significant methodological limitations which may account for the negative findings. One study 36 attempted to compare the impact on daytime performance of sleep disruption with and without SWS in 12 subjects; however, the experimental technique produced more than a 50% reduction in SWS in the "control" condition, versus an 85% reduction in the "no-SWS" condition. Finding differences in performance between 2 conditions with 50% and 85% reductions of SWS, with the additional influence of approximately 55-65 experimental arousals per night and total sleep times on disruption nights which range from 368 to 400 minutes in both conditions, would be unlikely and at least require a very large sample size. Studies by Lubin et al 37 and Johnson et al 38 deprived subjects of stage 4, not SWS, and therefore considerable SWS occurred. Compared to baseline, SWS was reduced by 78% and 63% in the 2 studies, respectively. Moreover, the sample size per experimental condition was 4 in the Lubin study and 7 in the Johnson study. The statistical power to detect differences in performance associated with sleep stage differences when sleep is highly disrupted by the experimental procedures is likely to be exceedingly low.
A related and equally important issue is whether SWS/SWA relate to insomnia in any way. The majority [39] [40] [41] of investigations, although not all, 42 of SWS in primary insomnia report mild to moderate reductions in SWS amounts. Depressed individuals who have an extremely high prevalence of insomnia have consistently been shown to have reduced SWS. 43 These associations of reduced SWS/SWA with insomnia are merely descriptive at the present time. However, combined with the finding that primary insomniacs have increased fast frequency EEG spectral power, 42, 44, 45 studies of insomnia and drugs which increase slow-frequency EEG activity seem logical.
In conclusion, this is the first demonstration that gaboxadol improves traditional hypnotic efficacy measures in a transient insomnia model. During phase advanced sleep gaboxadol 10 mg and 15 mg improved sleep relative to placebo on all PSG and self-report measures of hypnotic efficacy. Additionally, both visually scored SWS and spectral SWA measures showed a dose-related increase with gaboxadol. The spectral sleep EEG signature induced by gaboxadol-namely, the significantly increased SWA and theta, with decreased spindling activity-is very different from that induced by the BzRAs, consistent with a difference in the neural mechanism of action. Adverse events were infrequent, typically mild, and dose-related with gaboxadol. No residual effects were detected. Assessment of gaboxadol's efficacy, effectiveness, and safety in clinical populations and clarification of the physiologic and clinical significance of SWA enhancement are logical future research directions.
